• **Name:** Changsong Qi
• **Current Position & Affiliation:** Deputy chief Physician Peking University Cancer Hospital, Beijing, China
• **Country:** China

• Educational Background:

Sep.2006-Jul.2014 : Doctor of Medicine (MD) Peking University, Beijing, China

• Professional Experience:

• Sub-investigator. Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
• Sub-investigator. Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients with Advanced Digestive System Neoplasms.
• Sub-investigator. RD07 Cell Injection in the Treatment of Patients with Advanced Claudin18.2 Positive Solid Tumors.
• Sub-investigator. Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma.
• Sub-investigator. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection.
• Sub-investigator. A phase Ia/Ib, open-label, multicentre, dose-escalation, multidose study of CS1001 to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor efficacy in patients with advanced solid tumors or lymphoma.
• Sub-investigator. A Randomized,Double-Blind,Placebo-Controlled phase III Clinical Trial of Penbrolizumab(MK 3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5 Fluorouracil as First-Line Treatment in subjects with Advanced/Metastatic Esophageal Carcinoma(KEYNOTE-590).
• Sub-investigator. A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
• Sub-investigator. A Randomized, multicenter, controlled, adaptive II/III study to compare neoadjuvant chemotherapy of Docetaxel, Oxaliplatin combined with S-1(DOS) versus Oxaliplatin combined with S-1(SOX) in locally advanced gastric adenocarcinoma (RESOLVE-2 study).
• Sub-investigator. Randomized, open, multi-center Study of S-1+oxaliplatin versus S-1+ cisplatin in patients with metastatic, diffuse-type gastric adenocarcinoma.

• Professional Organizations:

- Member of American Society of Clinical Oncology (ASCO)
- Member of European Society for Medical Oncology (ESMO)
- Member of Chinese Society of Clinical Oncology (CSCO)
- Member of Chinese Anti-Cancer Association (CACA)
- Member of Chinese Gastrointestinal Oncology Group (CGOG)
- Core Member of CSCO Young, 2019-present

• Main Scientific Publications:

• Changsong Qi#*, Chang Liu#, Jifang Gong#, Dan Liu, Xicheng Wang, Panpan Zhang, Yanru Qin, Sai Ge, Miao Zhang, Zhi Peng, Jun Zhou, Zhihao Lu, Ming Lu, Yanshuo Cao, Jiajia Yuan, Yakun Wang, Zhenghang Wang, Ran Xue, Xiaohui Peng, Yumeng Wang, Daijing Yuan, Jian Li*, Xiaotian Zhang*, Lin Shen*. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med, 2024 Aug;30(8):2224-2234.

• Changsong Qi#, Jifang Gong#, Jian Li#, Dan Liu, Yanru Qin, Sai Ge, Miao Zhang, Zhi Peng, Jun Zhou, Yanshuo Cao, Xiaotian Zhang, Zhihao Lu, Ming Lu, Jiajia Yuan, Zhenghang Wang, Yakun Wang, Xiaohui Peng, Huiping Gao, Zhen Liu, Huamao Wang, Daijing Yuan, Jun Xiao, Hong Ma, Wei Wang, Zonghai Li, Lin Shen*. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med, 2022 Jun;28(6):1189-1198.

• Izuma Nakayama#, Changsong Qi#, Yang Chen, Yoshiaki Nakamura, Lin Shen*, Kohei Shitara*. Claudin 18.2 as a novel therapeutic target, Nat Rev Clin Oncol. 2024 May;21(5):354-369.

• Changsong Qi#*, Panpan Zhang#, Chang Liu, Jun Zhang, Jun Zhou, Jiajia Yuan, Dan Liu, Miao Zhang, Jifang Gong, Xicheng Wang, Jian Li, Xiaotian Zhang, Ning Li, Xiaohui Peng, Zhen Liu, Daijing Yuan, Raffaele Baffa, Yumeng Wang, Lin Shen. Safety and Efficacy of CT041 in Patients with Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials. Journal of Clinical Oncology, 2024 Jul 20;42(21):2565-2577.

• Changsong Qi #*, Dongqun Liu #, Chang Liu #, Xiaofei Wei, Mingyang Ma, Xinan Lu, Min Tao, Cheng Zhang, Xicheng Wang, Ting He, Jian Li, Fei Dai, Yanping Ding, Lin Shen*. Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells. J Immunother Cancer. 2024 Oct 4;12(10): e009960.

• Changsong Qi#; Tong Xie#; Jun Zhou#; Xicheng Wang; Jifang Gong; Xiaotian Zhang; Jian Li; Jiajia Yuan; Chang Liu; Lin Shen*. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer, Journal of Hematology & Oncology, 2023, 16(1): 102-102.

• Changsong Qi#*, Ting Zhou#, Yuezong Bai#, Hui Chen, Jiajia Yuan, Feilong Zhao, Chang Liu, Mingyang Ma, Ting Bei, Shiqing Chen, Xiaochen Zhao, Chunzhu Chen, Lin Shen*. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment. Int J Cancer, 2023 Dec 1;153(11):1916-1927.